跳到主要内容

使用LLMs回答科学问题

背景

以下提示测试LLM执行科学问题回答的能力。

提示

根据以下上下文回答问题。保持答案简短和简明。如果不确定答案,请回答“不确定答案”。

上下文:Teplizumab的起源可以追溯到新泽西的一家名为Ortho Pharmaceutical的制药公司。在那里,科学家们生成了抗体的早期版本,称为OKT3。这种分子最初来自于小鼠,能够结合到T细胞表面并限制其杀伤潜力。1986年,它被批准用于防止肾移植后的器官排斥,成为第一个被允许用于人类的治疗性抗体。

问题:OKT3最初来源于什么?
答案:

代码 / API

from openai import OpenAI
client = OpenAI()

response = client.chat.completions.create(
model="gpt-4",
messages=[
{
"role": "user",
"content": "Answer the question based on the context below. Keep the answer short and concise. Respond \"Unsure about answer\" if not sure about the answer.\n\nContext: Teplizumab traces its roots to a New Jersey drug company called Ortho Pharmaceutical. There, scientists generated an early version of the antibody, dubbed OKT3. Originally sourced from mice, the molecule was able to bind to the surface of T cells and limit their cell-killing potential. In 1986, it was approved to help prevent organ rejection after kidney transplants, making it the first therapeutic antibody allowed for human use.\n\nQuestion: What was OKT3 originally sourced from?\nAnswer:"
}
],
temperature=1,
max_tokens=250,
top_p=1,
frequency_penalty=0,
presence_penalty=0
)

参考